Mavyret Is Expected to Boost AbbVie’s Hepatitis C Revenue in 2018
The company reported HCV drug sales of $214 million in the US market, a YoY rise of more than 100%. In 4Q17, international markets contributed ~$296 million to AbbVie’s HCV revenue, a YoY rise of ~14.5% on an operational basis and of 15.4% on a reported basis.